Your browser doesn't support javascript.
loading
Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181).
Powderly, John; Spira, Alexander; Kondo, Shunsuke; Doi, Toshihiko; Luke, Jason J; Rasco, Drew; Gao, Bo; Tanner, Minna; Cassier, Philippe A; Gazzah, Anas; Italiano, Antoine; Tosi, Diego; Afar, Daniel E; Parikh, Apurvasena; Engelhardt, Benjamin; Englert, Stefan; Lambert, Stacie L; Kasichayanula, Sreeneeranj; Mensing, Sven; Menon, Rajeev; Vosganian, Gregory; Tolcher, Anthony.
Affiliation
  • Powderly J; Carolina BioOncology Institute, Huntersville, North Carolina, USA.
  • Spira A; Virginia Cancer Specialists, Fairfax, Virginia, USA.
  • Kondo S; Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
  • Doi T; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
  • Luke JJ; Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan.
  • Rasco D; Division of Hematology/Oncology, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
  • Gao B; START Center for Cancer Care, San Antonio, Texas, USA.
  • Tanner M; Blacktown Cancer and Haematology Centre, Blacktown, Australia.
  • Cassier PA; Department of Oncology, Tampere University Hospital, Tampere, Finland.
  • Gazzah A; Department of Medical Oncology, Centre Léon Bérard, Lyon, France.
  • Italiano A; Drug Development Department, Gustave Roussy Université Paris-Saclay, Villejuif, France.
  • Tosi D; Department of Medical Oncology, Institut Bergonié, Bordeaux, France.
  • Afar DE; Department of Medical Oncology, Institut Régional du Cancer de Montpellier, Montpellier, France.
  • Parikh A; Oncology Early Development, AbbVie, Inc., Redwood City, California, USA.
  • Engelhardt B; Clinical Pharmacology and Pharmacometrics, AbbVie, Inc., Redwood City, California, USA.
  • Englert S; Clinical Pharmacology and Pharmacometrics, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen am Rhein, Germany.
  • Lambert SL; Data and Statistical Sciences, AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany.
  • Kasichayanula S; Oncology Early Development, AbbVie, Inc., Redwood City, California, USA.
  • Mensing S; Clinical Pharmacology and Pharmacometrics, AbbVie, Inc., Redwood City, California, USA.
  • Menon R; Clinical Pharmacology and Pharmacometrics, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen am Rhein, Germany.
  • Vosganian G; Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, Illinois, USA.
  • Tolcher A; Oncology Early Development, AbbVie, Inc., Redwood City, California, USA.
Clin Transl Sci ; 14(1): 277-287, 2021 01.
Article in En | MEDLINE | ID: mdl-32770720
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Programmed Cell Death 1 Receptor / Immune Checkpoint Inhibitors / Models, Biological / Neoplasms Type of study: Clinical_trials / Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Clin Transl Sci Year: 2021 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Programmed Cell Death 1 Receptor / Immune Checkpoint Inhibitors / Models, Biological / Neoplasms Type of study: Clinical_trials / Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Clin Transl Sci Year: 2021 Type: Article Affiliation country: United States